Clinical Trials Browser

Phase 1 × Carcinoma, Non-Small-Cell Lung × MLN 8237 × Clear all

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms